Nateglinide

CAS No. 105816-04-4

Nateglinide ( A-4166; SDZ-DJN 608 )

Catalog No. M10264 CAS No. 105816-04-4

Nateglinide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM).

Purity : >98%(HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
10MG 37 In Stock
25MG 75 In Stock
50MG 133 In Stock
100MG 224 In Stock
200MG 323 In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    Nateglinide
  • Note
    Research use only, not for human use.
  • Brief Description
    Nateglinide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM).
  • Description
    Nateglinide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It belongs to the meglitinide class of short-acting insulin secretagogues, which act by binding to cells of the pancreas to stimulate insulin release. Nateglinide is an amino acid derivative that induces an early insulin response to meals decreasing postprandial blood glucose levels. It should only be taken with meals and meal-time doses should be skipped with any skipped meal. Approximately one month of therapy is required before a decrease in fasting blood glucose is seen. Meglitnides may have a neutral effect on weight or cause a slight increase in weight. The average weight gain caused by meglitinides appears to be lower than that caused by sulfonylureas and insulin and appears to occur only in those nave to oral antidiabetic agents. Due to their mechanism of action, meglitinides may cause hypoglycemia although the risk is thought to be lower than that of sulfonylureas since their action is dependent on the presence of glucose. In addition to reducing postprandial and fasting blood glucose, meglitnides have been shown to decrease glycosylated hemoglobin (HbA1c) levels, which are reflective of the last 8-10 weeks of glucose control. Meglitinides appear to be more effective at lowering postprandial blood glucose than metformin, sulfonylureas and thiazolidinediones. Nateglinide is extensively metabolized in the liver and excreted in urine (83%) and feces (10%). The major metabolites possess less activity than the parent compound. One minor metabolite, the isoprene, has the same potency as its parent compound.
  • Synonyms
    A-4166; SDZ-DJN 608
  • Pathway
    Cell Cycle/DNA Damage
  • Target
    Potassium Channel
  • Recptor
    Potassium Channel; PPARγ
  • Research Area
    Cardiovascular Disease
  • Indication
    ——

Chemical Information

  • CAS Number
    105816-04-4
  • Formula Weight
    317.42
  • Molecular Formula
    C19H27NO3
  • Purity
    >98%(HPLC)
  • Solubility
    Ethanol: 63 mg/mL (198.47 mM); DMSO: 63 mg/mL (198.47 mM)
  • SMILES
    O=C(O)[C@@H](CC1=CC=CC=C1)NC([C@H]2CC[C@H](C(C)C)CC2)=O
  • Chemical Name
    (R)-2-((1r,4R)-4-isopropylcyclohexanecarboxamido)-3-phenylpropanoic acid

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1.Hu S, et al. J Pharmacol Exp Ther. 2000 May;293(2):444-52.
molnova catalog
related products
  • Potassium Channel Ac...

    Potassium Channel Activator 1 can be used in studies about the treatment of disorders or conditions wherein the dopaminergic system is disrupted such as mood disorders ADHD, schizophrenia, and other psychotic states.

  • E-4031 dihydrochlori...

    E-4031 is a class III antiarrhythmic agent that binds to Kv11.1 (hERG) and blocks the rapid delayed-rectifier K+ current (IKr).

  • SKA31

    SKA 31 is an activator of KCa3.1 and KCa2 channels (EC50s: 260 2900 2900 nM for KCa3.1 KCa2.1 and KCa2.2 respectively).